? GENOMICS SHARED RESOURCE (GSR) The mission of the GSR is to support OSUCCC members and high-impact cancer research projects with genomics expertise, instrumentation and centralized resources to generate high-quality data. The GSR is a state- of-the-art genomics laboratory that has substantially increased capacity through expansion to shared resources at Nationwide Children?s Hospital. The GSR has the following Specific Aims: 1) sequence DNA and RNA templates using both next generation sequencing platforms (i.e. Ilumina HiSeq4000 and NovaSeq6000) and capillary Sanger sequencing and genotyping (via ABI 3730XL DNA Analyzers); 2) use sensitive molecular hybridization methods to detect and quantify RNA transcript expression levels and structures such as splicing and/or DNA copy numbers and variation, including digital (NanoString) and microarray (Affymetrix) platforms; and 3) perform polymerase chain reaction (PCR)-based amplification to detect, quantify and confirm copy number variants, single nucleotide variants, gene expression, and small insertion/deletion polymorphisms including quantitative PCR (QuantStudio 12K flex) and high-throughput digital and custom PCR assay (BiomarkHD and Juno) technologies. In 2018, the GSR partnered with the Institute for Genomic Medicine (IGM) at Nationwide Children?s Hospital (NCH) to expand our next-generation sequencing (NGS) technology services. The GSR co-Directors are Drs. Amanda Toland (MCC) and Richard Wilson (CB). The GSR provides essential genomics expertise and instrumentation to members of all five programs. During the current funding cycle, the GSR contributed to 338 publications (63 > 10 impact factor) and 94 grants from members of all five programs. We have been highly responsive to changing technology and user needs and, as a result, we now offer Sanger sample pick-up, cell line verification, and single-cell (sc) RNA sequencing. We also regularly host technology- based seminars or workshops to introduce new technology to OSUCCC members. With OSUCCC and institutional support, we have expanded our facilities to improve sequencing capabilities and to include nanofluidics liquid handlers and library preparation systems for sc-sequencing to provide state-of-the-art resolution in cancer biology and response to therapy. In the next funding cycle, the GSR will support the genomics needs of all OSU strategic priorities. Given the robust OSUCCC recruitment, demand for services and new technologies will increase. The GSR will expand its staff, instrumentation and services before capacity is reached. New services under development include isolation of circulating tumor cells for down-stream culturing and genomic profiling, purchasing an instrument and developing protocols for spatial transcriptomics, purchasing an instrument for sc-DNA sequencing, and optimizing protocols for other sc-genomics and low-input NanoString applications. The annual budget of the GSR is $2,634,443, yet the CCSG request is $231,495. As such, the GSR leverages extensive institutional support and seeks only 8.8% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090011
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Orchard, Tonya S; Andridge, Rebecca R; Yee, Lisa D et al. (2018) Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. J Acad Nutr Diet 118:578-588.e1
Reiff, Sean D; Mantel, Rose; Smith, Lisa L et al. (2018) The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discov 8:1300-1315
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
Qian, Maoxiang; Cao, Xueyuan; Devidas, Meenakshi et al. (2018) TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. J Clin Oncol 36:591-599
Myers, Regina M; Hill, Brian T; Shaw, Bronwen E et al. (2018) Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer 124:816-825
Nemeth, Julianna M; Thomson, Tiffany L; Lu, Bo et al. (2018) A social-contextual investigation of smoking among rural women: multi-level factors associated with smoking status and considerations for cessation. Rural Remote Health 18:4338
Mace, Thomas A; Shakya, Reena; Pitarresi, Jason R et al. (2018) IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67:320-332
Massengill, James B; Sample, Klarke M; Pilarski, Robert et al. (2018) Analysis of the exome aggregation consortium (ExAC) database suggests that the BAP1-tumor predisposition syndrome is underreported in cancer patients. Genes Chromosomes Cancer 57:478-481
Buteyn, Nathaniel J; Fatehchand, Kavin; Santhanam, Ramasamy et al. (2018) Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. Int Immunol 30:375-383
Hamilton, C A; Miller, A; Casablanca, Y et al. (2018) Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol 148:275-280

Showing the most recent 10 out of 2602 publications